Pfizer Bids Farewell To Blue Pill With New Double Helix Logo
'Reveals DNA At Heart' Of Science-Focused Firm
Executive Summary
CEO Albert Bourla says the rebranding "marks the advent of the new Pfizer – the culmination of a bold, decade-long transformation from a scientific fast follower to a first-in-class scientific powerhouse."
You may also be interested in...
Quick Listen: Scrip’s Five Must-Know Things
Join us for an audio catch-up on the latest major developments in the global biopharma industry, as reported by Scrip's global team, in this mini podcast version of Five Must-Know Things.
Poland’s Ryvu Bets Big On Blood Cancer Candidate
Ryvu has only about $7m in cash and equivalents but believes that a mixture of venture debt, milestones from partners and tapping the equity capital markets will provide the funds to advance RVU120 for acute myeloid leukemia and myelodysplastic syndrome.
Acticor Makes Case For First-In-Class Heart Drug Glencozimab
As it initiates the mid-stage clinical program for glencozimab, Acticor says that the potential of the drug in ischemic stroke alone could make it a blockbuster.